Breaking News Instant updates and real-time market news.

DRRX

Durect

$1.31

0.01 (0.77%)

, NVS

Novartis

$80.83

0.38 (0.47%)

07:03
06/19/17
06/19
07:03
06/19/17
07:03

Durect collaboration with Sandoz clears HSR review, now effective

DURECT (DRRX) announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR, an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and has become effective. Under the terms of the agreement, Sandoz has made an upfront payment to DURECT of $20M, with the potential for up to an additional $43M in development and regulatory milestones, up to an additional $230M in sales-based milestones, as well as a tiered double-digit royalty on product sales in the United States. DURECT remains responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval.

DRRX

Durect

$1.31

0.01 (0.77%)

NVS

Novartis

$80.83

0.38 (0.47%)

  • 26

    Jun

DRRX Durect
$1.31

0.01 (0.77%)

02/28/17
HCWC
02/28/17
INITIATION
Target $3
HCWC
Buy
Durect assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce assumed coverage of Durect with a Buy rating and $3 price target.
NVS Novartis
$80.83

0.38 (0.47%)

06/01/17
NEED
06/01/17
NO CHANGE
Target $4.5
NEED
Buy
Cryoport price target raised to $4.50 from $3.50 at Needham
Needham analyst Sean Hannan noted that Novartis (NVS) and Kite Pharma (KITE) both have Biologics License Applications nearing approval for studies believed to be supported by Cryoport (CYRX). Citing his growing comfort on clients' progress toward commercialization, he raised his price target on Cryoport to $4.50 from $3.50 and keeps a Buy rating on the "arms provider" to companies working on emerging regenerative therapies.
06/06/17
LEER
06/06/17
NO CHANGE
Target $100
LEER
Outperform
bluebird data among most impressive in CAR-T space, says Leerink
Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:37
01/17/18
01/17
07:37
01/17/18
07:37
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

GG

Goldcorp

$15.39

1.04 (7.25%)

07:37
01/17/18
01/17
07:37
01/17/18
07:37
Downgrade
Goldcorp rating change  »

Goldcorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Earnings
Goldman Sachs reports Q4 EPS $5.68 ex Tax Legislation, consensus $4.92 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

, RNG

RingCentral

$50.65

-1.7 (-3.25%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Upgrade
8x8, Inc., RingCentral rating change  »

8x8, Inc. upgraded to…

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

RNG

RingCentral

$50.65

-1.7 (-3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 25

    Jan

ORCL

Oracle

$49.59

0.08 (0.16%)

, PBR

Petrobras

$11.70

0.23 (2.01%)

07:35
01/17/18
01/17
07:35
01/17/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

ORCL

Oracle

$49.59

0.08 (0.16%)

PBR

Petrobras

$11.70

0.23 (2.01%)

AMAT

Applied Materials

$54.50

1.05 (1.96%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KMI

Kinder Morgan

$19.39

-0.13 (-0.67%)

KODK

Kodak

$8.50

-0.7 (-7.61%)

MGM

MGM Resorts

$36.03

1 (2.85%)

PX

Praxair

$162.10

-2.05 (-1.25%)

PVG

Pretium Resources

$11.65

0.5 (4.48%)

PAAS

Pan American Silver

$17.24

0.58 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 21

    Feb

  • 25

    Mar

07:35
01/17/18
01/17
07:35
01/17/18
07:35
General news
U.S. MBA mortgage market index rose 4.1% »

U.S. MBA mortgage market…

07:33
01/17/18
01/17
07:33
01/17/18
07:33
Conference/Events
Federal Reserve Bank of Cleveland President speaks on monetary policy »

Cleveland Federal Reserve…

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

, AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:33
01/17/18
01/17
07:33
01/17/18
07:33
Conference/Events
Strongbridge Biopharma to host conference call »

Conference call to…

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

XRAY

Dentsply Sirona

$65.65

-0.14 (-0.21%)

07:32
01/17/18
01/17
07:32
01/17/18
07:32
Hot Stocks
Dentsply Sirona appoints Donald Casey Jr. as CEO »

Dentsply Sirona announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Conference/Events
Federal Reserve Bank of Dallas President participates in a discussion »

Dallas Federal Reserve…

LCII

LCI Industries

$123.65

-2.75 (-2.18%)

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Hot Stocks
LCI Industries to acquire Taylor Made Group, terms not disclosed »

LCI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNHI

CNH Industrial

$14.72

-0.21 (-1.41%)

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Initiation
CNH Industrial initiated  »

CNH Industrial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

PAVM

PAVmed

$2.84

-0.12 (-4.05%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Hot Stocks
PAVmed announces terms of previously announced rights offering »

PAVmed Iannounced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$101.06

-0.23 (-0.23%)

, SPLK

Splunk

$87.13

-2.51 (-2.80%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Conference/Events
House Homeland Security Committee to hold a hearing »

The Cybersecurity and…

DXC

DXC Technology

$101.06

-0.23 (-0.23%)

SPLK

Splunk

$87.13

-2.51 (-2.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

GME

GameStop

$17.16

-0.6 (-3.38%)

, AREX

Approach Resources

$3.62

-0.29 (-7.42%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GME

GameStop

$17.16

-0.6 (-3.38%)

AREX

Approach Resources

$3.62

-0.29 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Aeterna Zentaris »

Aeterna Zentaris trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKS

Dick's Sporting

$32.33

-1 (-3.00%)

07:29
01/17/18
01/17
07:29
01/17/18
07:29
Upgrade
Dick's Sporting rating change  »

Dick's Sporting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$132.14

-0.39 (-0.29%)

07:29
01/17/18
01/17
07:29
01/17/18
07:29
Recommendations
VMware analyst commentary  »

VMware price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 19

    Jan

07:28
01/17/18
01/17
07:28
01/17/18
07:28
Conference/Events
Fitch Ratings to hold a teleconference »

Fitch Analysts provide…

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Conference/Events
The Executives' Club of Chicago holds a luncheon meeting »

The Executives' Club…

TI

Telecom Italia

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Downgrade
Telecom Italia rating change  »

Telecom Italia downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DF

Dean Foods

$11.28

0.01 (0.09%)

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Upgrade
Dean Foods rating change  »

Dean Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

07:27
01/17/18
01/17
07:27
01/17/18
07:27
Upgrade
Telefonica rating change  »

Telefonica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.